Infliximab for the Treatment of Fistulas in Patients with Crohn's Disease
- 6 May 1999
- journal article
- clinical trial
- Published by Massachusetts Medical Society in The New England Journal of Medicine
- Vol. 340 (18), 1398-1405
- https://doi.org/10.1056/nejm199905063401804
Abstract
Enterocutaneous fistulas are a serious complication of Crohn's disease and are difficult to treat. Infliximab, a chimeric monoclonal antibody to tumor necrosis factor α, has recently been developed as a treatment for Crohn's disease. We conducted a randomized, multicenter, double-blind, placebo-controlled trial of infliximab for the treatment of fistulas in patients with Crohn's disease.Keywords
This publication has 23 references indexed in Scilit:
- Treatment of Crohn's disease with anti-tumor necrosis factor chimeric monoclonal antibody (cA2)Gastroenterology, 1995
- Chimeric anti-TNF-α monoclonal antibody cA2 binds recombinant transmembrane TNF-α and activates immune effector functionsCytokine, 1995
- The Mouse/Human Chimeric Monoclonal Antibody cA2 Neutralizes TNF In Vitro and Protects Transgenic Mice from Cachexia and TNF Lethality In VivoCytokine, 1995
- Usual Therapy Improves Perianal Crohn??s Disease as Measured by a New Disease Activity IndexJournal of Clinical Gastroenterology, 1995
- Efficacy of cyclosporine in treatment of fistula of crohn's diseaseDigestive Diseases and Sciences, 1994
- Cytokines (Immunoinf lammatory Hormones) and Their Natural Regulation in Inflammatory Bowel Disease (Crohn’s Disease and Ulcerative Colitis): A ReviewDigestive Diseases, 1994
- Construction and initial characterization of a mouse-human chimeric anti-TNF antibodyMolecular Immunology, 1993
- Lymphoma in inflammatory bowel diseaseCancer, 1992
- Anal complications in Crohn's diseaseDiseases of the Colon & Rectum, 1981
- Treatment of Crohn's Disease with 6-MercaptopurineThe New England Journal of Medicine, 1980